This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The aim of the study was to evaluate the cost-effectiveness of ustekinumab compared with etanercept among adults with moderate to severe plaque psoriasis who had an inadequate response or contraindications to at least one conventional systemic therapy or phototherapy (such as ultraviolet B rays).
Interventions
Ustekinumab administered at a dose of 45mg at week zero and week four was compared with etanercept administered at a dose of 50mg biweekly for 12 weeks. Both interventions were given by subcutaneous injection.
Location/setting
Canada/secondary care.
Methods

Analytical approach:
A Markov model was used to combine data from a single study with data from published evidence. This model followed the psoriasis assumptions from the health technology assessment (HTA) report undertaken by the Centre for Reviews and Dissemination (CRD), University of York, UK. The time horizon of the study was 10 years. The perspective was that of the Ontario Ministry of Health, Canada.
Effectiveness data:
Effectiveness data was from the 12-week Active Comparator Psoriasis Trial (ACCEPT). This was a phase three multicentre randomised controlled trial. The study included 903 adult patients who were randomised between etanercept (347 patients), ustekinumab 45mg (209 patients) and ustekinumab 90mg (347 patients). Only the ustekinumab 45mg group was used in the model. The study had a follow-up period of 12 weeks. The main clinical effectiveness estimate was the Psoriasis Area and Severity Index (PASI) 75 score collected from patients at week 12.
The trial results were extrapolated for the model using published literature and a Delphi panel of Canadian experts.
Monetary benefit and utility valuations:
Utility gains were applied to patients regardless of treatment arm in accordance with the PASI change from baseline achieved in the ACCEPT study. PASI data did not provide utility scores, so the Dermatology Life Quality Index (DLQI) index was transformed to utility values through linear regression. The regression analysis used data from the Health Outcomes Data Repository where both EuroQol-5D (EQ-5D) and DLQI were collected from patients. ACCEPT
